(EN) The present invention relates to a composition for preventing and treating colorectal cancer, comprising streptonigrin and an immune checkpoint inhibitor as active ingredients. The present inventors have confirmed that streptonigrin not only significantly reduces the survival rate of a colorectal cancer cell line, but also increases the expression of the PD-L1 protein in the colorectal cancer cell line. Said result shows that streptonigrin may restore the immune sensitivity of the colorectal cancer cell line, thereby promoting the effect of an anti-PD-1 antibody, and thus the present invention is expected to enable effective treatment of colorectal cancer by means of the co-administration of streptonigrin and the anti-PD-1 antibody.
(FR) La présente invention concerne une composition pour la prévention et le traitement du cancer colorectal, comprenant de la streptonigrine et un inhibiteur de de point de contrôle immunitaire comme principes actifs. Les présents inventeurs ont confirmé que la streptonigrine non seulement réduit de manière significative le taux de survie d'une lignée de cellules du cancer colorectal, mais augmente également l'expression de la protéine PD-L1 dans la lignée de cellules du cancer colorectal. Ledit résultat montre que la streptonigrine peut restaurer la sensibilité immunitaire de la lignée de cellules du cancer colorectal, ce qui favorise l'effet d'un anticorps anti-PD-1, et ainsi la présente invention est censée permettre un traitement efficace du cancer colorectal au moyen de la co-administration de streptonigrine et de l'anticorps anti-PD-1.
(KO) 본 발명은 스트렙토니그린 및 면역관문 억제제를 유효성분으로 포함하는 대장암 예방 및 치료용 조성물 등에 관한 것으로, 본 발명자들은 스트렙토니그린이 대장암 세포주의 생존률을 유의하게 감소시킬 뿐만 아니라, 대장암 세포주에서 PD-L1 단백질의 발현을 증가시키는 것을 확인하였다. 이는 스트렙토니그린이 대장암 세포주의 면역 민감성을 회복시켜 항 PD-1 항체의 효과를 촉진시킬 것임을 나타내는 바, 스트렙토니그린 및 항 PD-1 항체의 병용으로 대장암을 효과적으로 치료할 수 있을 것으로 기대된다.
